Senseera, a Jerusalem, Israel-based liquid biopsy firm, raised $7.1M in Seed funding.
The spherical was led by Lightspeed Enterprise Companions, with participation from I-Subsequent Capital and the Lowy Medical Analysis Institute.
The corporate intends to make use of the funds to advance its GEM BIOMARKERS™ liquid biopsy platform, empowered by cfChIP-seq expertise.
Led by CEO Dr. Ronen Sadeh, Senseera gives a platform, GEM BIOMARKERS™, that helps drug improvement in most cancers and immune issues. By providing simultaneous stable tissue and immune cell states monitoring, the platform additionally gives insights into tissue/tumor immune cross-talk, enabling researchers and clinicians to higher perceive the underlying mechanisms and help personalised therapies.
FinSMEs
07/01/2025
